FindTrial
Sign In

Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer

Phase II Evaluation of Weekly Docetaxel in Combination With Weekly Carboplatin in the Treatment of Recurrent Epithelial Ovarian Carcinoma

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00214058
Enrollment
36
Registered
2005-09-21
Start date
2002-08-31
Completion date
2006-02-28
Last updated
2019-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Carcinoma, Primary Peritoneal Carcinoma

Brief summary

The purpose of this study is to determine the safety and efficacy of this regimen in women with ovarian or peritoneal cancer

Interventions

DRUGCarboplatin
DRUGDocetaxel

Sponsors

Aventis Pharmaceuticals
CollaboratorINDUSTRY
University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum

Inclusion criteria

* Recurrent ovarian or peritoneal cancer

Exclusion criteria

* No prior chemotherapy

Design outcomes

Primary

MeasureTime frame
Safety and Efficacy—

Secondary

MeasureTime frame
QOL—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026